This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Seattle Genetics: A Short Thesis That's Been Right And Wrong

Stocks in this article: SGEN

The phase II retreatment data presented in June look good in sALCL (88% overall response rate) and decent in HL (56% response rate.) Unfortunately, the study included only 8 patients in sALCL and 16 patients in HL. The more compelling results are in the far smaller sALCL treatment market.

At next month's American Society of Hematology (ASH) conference, investigators will present long-term data on the use of Adcetris in relapsed HL and sALCL, a phase I study of the drug in front-line sALCL, and a single arm phase II trial in several subtypes of relapsed non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). Although these data may provide justification for further exploratory studies, none of the abstracts seem likely to meaningfully alter oncology practice patterns near-term.

Seattle Genetics' executives believe Adcetris will eventually become a billion-dollar drug. I doubt it, but let's consider that possibility. To reach this level, the company will surely need positive results from ongoing phase III trials. I don't have a strong opinion on those studies yet, but let's generously imagine Adcetris sales peak at $1.5 billion in 2022. Even if we apply a five-times multiple to those sales, discounting for time reduces the present value of Adcetris to $2.4 billion, roughly in-line with the company's current enterprise value.

Bulls contend Seattle Genetics has other partnered drugs in early clinical development that could unlock additional value. I'm sure they believe my sales estimates are too low, too. I have yet to read or hear an argument that would change my mind. The ASH conference seems to me the last positive catalyst for awhile. (Yes, I know Adcetris will likely receive European approval within the next few months, but that's widely expected and the drug's commercial potential ex-US remains highly uncertain.)

Basically, I don't really see a compelling investment thesis for Seattle Genetics long or short. Feuerstein was on point with his tweet: I've been right about Adcetris but wrong on the stock. Even though sales will continue to drag and could even decline slightly over the next few quarters, I'm not sure there will be enough bad news to make Seattle Genetics shares decline further.

If Seattle Genetics shares do move meaningfully downward, it will likely be due to either a broader market correction (hard to predict) or because some of the company's shareholders lose patience and bail. That doesn't make for a very interesting investment thesis, so I'm moving to the sidelines.

Sometimes, even when you're right, you're wrong.

Sadeghi has no position in Seattle Genetics.

Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza's Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs